FrançaisElevance Health (ELV): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 17.9 | The higher, the more growth the market expects. |
| Forward P/E | 13.9 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | 1.00 | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 3% | Share of revenue that ends up as profit. |
| Revenue growth | 1% | Pace of revenue growth. |
| Price-to-book | 2.0 | Price relative to book value. |
| Market cap | $91.5 B | Total market value of the company. |
| Dividend yield | 1.65% | Annual dividend ~$6.86/share relative to price. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $155.7 B | $6.0 B | 4% |
| 2023 | $170.2 B | $6.0 B | 4% |
| 2024 | $175.2 B | $6.0 B | 3% |
| 2025 | $197.6 B | $5.7 B | 3% |
📊 Open the interactive Elevance Health page (charts, live news) →
Frequently asked questions
Is Elevance Health stock expensive?
Elevance Health has a P/E of 17.9 (forward P/E 13.9) and a PEG of 1.00. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: reasonable valuation.
What is Elevance Health's net margin?
Elevance Health's net margin is about 3% — the share of revenue that ends up as net profit.
What is Elevance Health's revenue?
Latest known revenue: $197.6 B for net income of $5.7 B. The year-by-year breakdown is in the income statement above.
What is Elevance Health's market cap?
Elevance Health (ELV) has a market cap of about $91.5 B.
Does Elevance Health pay a dividend?
Yes: Elevance Health pays about $6.86/share per year, i.e. roughly a 1.65% yield at the current price.
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.